A Phase 3 interventional study of VX-809 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 54 sites in 9 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-10-23.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 3, and was the 13th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2015.
This study's enrollment of 206 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 23rd largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 42nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
Drug: VX-809 · Drug: VX-770
Matching placebo q12h
Drug: Placebo
Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24
Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: Baseline, Through Week 24
Average Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 4
Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Change from Baseline in sweat chloride at Day 15 and Week 4 was calculated. The average of the 2 values (Change at Day 15 and Week 4) was reported.
Time frame: Baseline, Day 15 and Week 4
Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
BMI was defined as weight in kg divided by height in square meter (m\^2).
Time frame: Baseline, Week 24
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Through Week 24
Absolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 24
LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
Time frame: Baseline, Through Week 24
Absolute Change From Baseline in Sweat Chloride at Week 24
Sweat samples were collected using an approved collection device.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).
Time frame: Baseline, Through Week 24
Relative Change From Baseline in ppFEV1 Through Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).
Time frame: Baseline, Through Week 24
Absolute Change From Baseline in BMI-for-age Z-score at Week 24
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Weight at Week 24
Time frame: Baseline, Week 24
Absolute Change From Baseline in Weight-for-age Z-score at Week 24
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Height at Week 24
Time frame: Baseline, Week 24
Absolute Change From Baseline in Height-for-age Z-score at Week 24
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains Through Week 24
The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.
Time frame: Baseline, Through Week 24
Number of Pulmonary Exacerbation Events
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
Time frame: Baseline through Week 24
Percentage of Participants With At Least 1 Pulmonary Exacerbation Event
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: Baseline through Week 24
Time-to-first Pulmonary Exacerbation
Time-to-first pulmonary exacerbation was analyzed using the Kaplan-Meier estimates. Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: Baseline through Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.
Time frame: Baseline up to Week 28
Average Pre-dose Concentration (Ctrough,Ave) and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Ave) For Lumacaftor and Ivacaftor
Ctrough,ave is average of individual pre-dose observed concentrations across Week 4 and 24. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 1, 15 and Week 4. This outcome was not planned to be assessed in Placebo arm.
Time frame: For Ctrough,ave: before morning dose on Week 4 and 24; For C3-6h,ave: 3 to 6 hours after morning dose on Day 1, 15 and Week 4
| Milestone | Placebo | LUM/IVA |
|---|---|---|
| Started | 101 | 103 |
| Completed | 98 | 98 |
| Not completed | 3 | 5 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other | 1 | 1 |
Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| Ratio | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24 | 0.08 ± 0.13 | -1.01 ± 0.13 |
Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Change from Baseline in sweat chloride at Day 15 and Week 4 was calculated. The average of the 2 values (Change at Day 15 and Week 4) was reported.
| Millimole per liter (mmol/L) | Placebo | LUM/IVA |
|---|---|---|
| Average Absolute Change From Baseline in Sweat Chloride at Day 15 and Week 4 | 0.8 ± 1.0 | -20.0 ± 1.0 |
BMI was defined as weight in kg divided by height in square meter (m\^2).
| Kg/m^2 | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Body Mass Index (BMI) at Week 24 | 0.27 ± 0.07 | 0.38 ± 0.07 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| Units on a scale | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24 | 3.0 ± 1.0 | 5.5 ± 1.0 |
LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
| Ratio | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Lung Clearance Index 5.0 (LCI5.0) Through Week 24 | 0.08 ± 0.05 | -0.36 ± 0.05 |
Sweat samples were collected using an approved collection device.
| mmol/L | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Sweat Chloride at Week 24 | 3.2 ± 1.3 | -21.6 ± 1.3 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).
| Percent predicted of FEV1 | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24 | -1.3 ± 0.8 | 1.1 ± 0.8 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Wang standards were used to calculate ppFEV1 (for age, gender, race, and height).
| Percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative Change From Baseline in ppFEV1 Through Week 24 | -0.9 ± 1.0 | 2.2 ± 1.0 |
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| Z-score | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in BMI-for-age Z-score at Week 24 | 0.05 ± 0.04 | 0.08 ± 0.04 |
| Kg | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Weight at Week 24 | 1.7 ± 0.2 | 2.0 ± 0.1 |
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| Z-score | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Weight-for-age Z-score at Week 24 | 0.02 ± 0.02 | 0.06 ± 0.02 |
| Centimeter (cm) | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Height at Week 24 | 2.6 ± 0.1 | 2.9 ± 0.1 |
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.
| Z-score | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Height-for-age Z-score at Week 24 | 0.00 ± 0.02 | 0.03 ± 0.02 |
The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.
| Units on a scale | Placebo | LUM/IVA |
|---|---|---|
| Change Through Week 24: Effectiveness | 0.6 ± 1.5 | 1.7 ± 1.5 |
| Change Through Week 24: Side Effects | 0.4 ± 0.8 | -1.0 ± 0.8 |
| Change Through Week 24: Convenience | 9.9 ± 1.2 | 11.9 ± 1.2 |
| Change Through Week 24: Global Score | -2.3 ± 1.6 | -1.4 ± 1.6 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
| Pulmonary exacerbation events | Placebo | LUM/IVA |
|---|---|---|
| Number of Pulmonary Exacerbation Events | 18 | 24 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| Percentage of participants | Placebo | LUM/IVA |
|---|---|---|
| Percentage of Participants With At Least 1 Pulmonary Exacerbation Event | 14.9 | 19.4 |
Time-to-first pulmonary exacerbation was analyzed using the Kaplan-Meier estimates. Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| Days | Placebo | LUM/IVA |
|---|---|---|
| Time-to-first Pulmonary Exacerbation | NA (NA to NA) | NA (NA to NA) |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.
| participants | Placebo | LUM/IVA |
|---|---|---|
| Participants With Any Treatment-Emergent AEs | 98 | 98 |
| Participants With Treatment-Emergent SAEs | 11 | 13 |
Ctrough,ave is average of individual pre-dose observed concentrations across Week 4 and 24. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 1, 15 and Week 4. This outcome was not planned to be assessed in Placebo arm.
| Nanogram per milliliter (ng/mL) | LUM/IVA |
|---|---|
| LUM: Ctrough,ave | 10200 ± 4460 |
| LUM: C3-6h,ave | 20600 ± 6560 |
| IVA: Ctrough,ave | 107 ± 91.2 |
| IVA: C3-6h,ave | 821 ± 348 |
Collected over Baseline up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/101 (0%) | 11/101 (10.9%) | 98/101 (97%) |
| LUM/IVA | 0/103 (0%) | 13/103 (12.6%) | 98/103 (95.1%) |
| Event | Placebo | LUM/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 5/101 | 8/103 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 2/101 | 0/103 |
| Alanine aminotransferase increasedInvestigations | 1/101 | 0/103 |
| Aspartate aminotransferase increasedInvestigations | 1/101 | 0/103 |
| Transaminases increasedInvestigations | 1/101 | 0/103 |
| LymphadenitisBlood and lymphatic system disorders | 1/101 | 0/103 |
| Device related thrombosisGeneral disorders | 1/101 | 0/103 |
| ConstipationGastrointestinal disorders | 1/101 | 0/103 |
| PneumoniaInfections and infestations | 1/101 | 1/103 |
| Poor venous accessVascular disorders | 0/101 | 1/103 |
| Event | Placebo | LUM/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 47/101 | 46/103 |
| PyrexiaGeneral disorders | 20/101 | 15/103 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 6/101 | 18/103 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 8/101 | 17/103 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 16/101 | 13/103 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 10/101 | 15/103 |
| HeadacheNervous system disorders | 9/101 | 13/103 |
| Abdominal pain upperGastrointestinal disorders | 7/101 | 13/103 |
| Upper respiratory tract infectionInfections and infestations | 10/101 | 13/103 |
| FatigueGeneral disorders | 11/101 | 9/103 |
| Age, Continuous(years) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.59 | 8.7 ± 1.6 | 8.8 ± 1.59 |
| Sex: Female, Male(Participants) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| Female | 58 | 63 | 121 |
| Male | 43 | 40 | 83 |
The record gives a start of Jul 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →